Cost-effectiveness of 2-dose human papillomavirus vaccination for 12-year-old girls in Zhejiang Province: implications for China’s expanded program on immunization

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi:10.3322/caac.v68.6.
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32. doi:10.3322/caac.21338.
   PubMed Web of Science ®Google Scholar
• Human Papillomavirus and Related Diseases Report China. http://www.hpvcentre.net/statistics.php[EB/OL].
   Google Scholar
• Zhu FC, Hu SY, Hong Y, Hu Y-M, Zhang X, Zhang Y-J, Pan Q-J, Zhang W-H, Zhao F-H, Zhang C-F. Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18–25 years: event-triggered analysis of a randomized controlled trial. Cancer Med. 2017;6:12–25. doi:10.1002/cam4.2017.6.issue-1.
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow S-N, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301–14. doi:10.1016/S0140-6736(09)61248-4.
   PubMed Web of Science ®Google Scholar
• Kostaras D, Karampli E, Athanasakis K. Vaccination against HPV virus: a systematic review of economic evaluation studies for developed countries. Expert Rev Pharmacoecon Outcomes Res. 2019;19:147–58. doi:10.1080/14737167.2019.1555039.
   PubMed Web of Science ®Google Scholar
• Setiawan D, Oktora MP, Hutubessy R, Riewpaiboon A, Postma MJ. The health-economic studies of HPV vaccination in Southeast Asian countries: a systematic review. Expert Rev Vaccines. 2017;16:933–43. doi:10.1080/14760584.2017.1357472.
   PubMed Web of Science ®Google Scholar
• Romanowski B, Schwarz TF, Ferguson LM, Ferguson M, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Behre U, et al. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study. Hum Vaccin Immunother. 2014;10:1155–65. doi:10.4161/hv.28022.
   PubMed Web of Science ®Google Scholar
• Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, González P, Solomon D, Jiménez S, Schiller JT, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. JNCI. 2011;103:1444–51. doi:10.1093/jnci/djr319.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Electronic address swi. Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations. Vaccine. 2017;35:5753–55. doi:10.1016/j.vaccine.2017.05.069.
   PubMed Web of Science ®Google Scholar
• Collier R. Two-dose HPV regimen recommended in US. CMAJ. 2017;189:E36. doi:10.1503/cmaj.109-5350.
   PubMed Web of Science ®Google Scholar
• Shapiro GK, Guichon J, Kelaher M. Canadian school-based HPV vaccine programs and policy considerations. Vaccine. 2017;35:5700–07. doi:10.1016/j.vaccine.2017.07.079.
   PubMed Web of Science ®Google Scholar
• Riesen M, Garcia V, Low N, Althaus CL. Modeling the consequences of regional heterogeneity in human papillomavirus (HPV) vaccination uptake on transmission in Switzerland. Vaccine. 2017;35:7312–21. doi:10.1016/j.vaccine.2017.10.103.
   PubMed Web of Science ®Google Scholar
• Organization WH. Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec. 2009;84:118–31.
   PubMedGoogle Scholar
• https://www.who.int/immunization/monitoring_surveillance/VaccineIntroStatus.pptx?ua=1.
   Google Scholar
• The Global alliance for vaccines and immunisation, HPV supply and procurement roadmap. https://www.gavi.org/library/gavi-documents/supply-procurement/hpv-supplyand-procurement–roadmap/.
   Google Scholar
• World Health Organization. WHO director-general calls for all countries to take action to help end the suffering caused by cervical cancer. 2018; http://www.who.int/reproductivehealth/call-to-action-elimination-cervical-cancer/en/.
   Google Scholar
• Qiao YL, Wu T, Li RC, Hu Y-M, Wei L-H, Li C-G, Chen W, Huang S-J, Zhao F-H, Li M-Q, et al. Efficacy, safety, and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine: an interim analysis of a randomized clinical trial. J Natl Cancer Inst. 2019. doi:10.1093/jnci/djz074.
   PubMedGoogle Scholar
• Hu Y, Guo M, Li C, Chu K, He W, Zhang J, Gu J, Li J, Zhao H, Wu X, et al. Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women. Sci China Life Sci. 2019. doi:10.1007/s11427-019-9547-7.
   Web of Science ®Google Scholar
• Zhao FH, Lewkowitz AK, Hu SY, Chen F, Li L-Y, Zhang Q-M, Wu R-F, Li C-Q, Wei L-H, Xu A-D, et al. Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies. Int J Cancer. 2012;131:2929–38. doi:10.1002/ijc.27571.
   PubMed Web of Science ®Google Scholar
• Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol. 1998;92:727–35. doi:10.1016/s0029-7844(98)00245-2.
   PubMed Web of Science ®Google Scholar
• Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E, Miller S, Clayton L, Farhat S, Broering J, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. Jama. 2001;285:2995–3002. doi:10.1001/jama.285.23.2995.
   PubMed Web of Science ®Google Scholar
• Van de Velde N, Brisson M, Boily MC. Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol. 2007;165:762–75. doi:10.1093/aje/kwk059.
   PubMed Web of Science ®Google Scholar
• Mo X, Gai Tobe R, Wang L, Liu X, Wu B, Luo H, Nagata C, Mori R, Nakayama T. Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China. BMC Infect Dis. 2017;17:502. doi:10.1186/s12879-017-2592-5.
   PubMed Web of Science ®Google Scholar
• Sinanovic E, Moodley J, Barone MA, Mall S, Cleary S, Harries J. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa. Vaccine. 2009;27:6196–202. doi:10.1016/j.vaccine.2009.08.004.
   PubMed Web of Science ®Google Scholar
• Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993;12:186–92. doi:10.1097/00004347-199304000-00018.
   PubMed Web of Science ®Google Scholar
• Gong W, Luo S, Hu R, Wang H, Pan J, Fei F, He Q, Yu M. Analysis of survival rate of breast, cervical, and ovarian cancer patients during 2005–2010 in Zhejiang province, China. Zhonghua Yu Fang Yi Xue Za Zhi. 2014;48:366–69.
   PubMedGoogle Scholar
• Zhang Q, Liu YJ, Hu SY, Zhao FH. Estimating long-term clinical effectiveness and cost-effectiveness of HPV 16/18 vaccine in China. BMC Cancer. 2016;16:848. doi:10.1186/s12885-016-2893-x.
   PubMed Web of Science ®Google Scholar
• Tao SY, Peng JR, Wang Y, Zhang GT, Chen ZY, Zhao F, Ma JQ, Yang X, Qiao YL, Zhao FH, et al. Study on direct economic burden and influencing factors in patients with cervical cancer and precancerous lesions. Zhonghua Yu Fang Yi Xue Za Zhi. 2018;52:1281–86. doi:10.3760/cma.j.issn.0253-9624.2018.12.017.
   PubMedGoogle Scholar
• Zhou YHH, Deng X, Yan R, Tang XW, Xie SY. Comparative analysis on actual cost and reasonable cost of expanded program on immunization in Zhejiang. Chin Health Econ. 2018;37:86–89.
   Google Scholar
• Silas OA, Achenbach CJ, Murphy RL, Hou L, Sagay SA, Banwat E, Adoga AA, Musa J, French DD. Cost effectiveness of human papilloma virus vaccination in low and middle income countries: a systematic review of literature. Expert Rev Vaccines. 2018;17:91–98. doi:10.1080/14760584.2018.1411195.
   PubMed Web of Science ®Google Scholar
• Fesenfeld M, Hutubessy R, Jit M. Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review. Vaccine. 2013;31:3786–804. doi:10.1016/j.vaccine.2013.06.060.
   PubMed Web of Science ®Google Scholar
• Prinja S, Bahuguna P, Faujdar DS, Jyani G, Srinivasan R, Ghoshal S, Suri V, Singh MP, Kumar R. Cost-effectiveness of human papillomavirus vaccination for adolescent girls in Punjab state: implications for India’s universal immunization program. Cancer. 2017;123:3253–60. doi:10.1002/cncr.v123.17.
   PubMed Web of Science ®Google Scholar
• Aljunid S, Maimaiti N, Nur AM, Noor MRM, Wan Puteh SE. Cost-effectiveness of HPV vaccination regime: comparing twice versus thrice vaccinations dose regime among adolescent girls in Malaysia. BMC Public Health. 2016;16:71. doi:10.1186/s12889-016-2754-1.
   PubMed Web of Science ®Google Scholar
• Jit M, Brisson M, Laprise JF, Choi YH. Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model. BMJ (Clinical Research Ed). 2015;350:g7584.
   PubMed Web of Science ®Google Scholar
• Jit M, Choi YH, Laprise JF, Boily MC, Drolet M, Brisson M. Two-dose strategies for human papillomavirus vaccination: how well do they need to protect? Vaccine. 2014;32:3237–42. doi:10.1016/j.vaccine.2014.03.098.
   PubMed Web of Science ®Google Scholar
• Pan XF, Griffiths UK, Pennington M, Yu H, Jit M. Systematic review of economic evaluations of vaccination programs in mainland China: are they sufficient to inform decision making? Vaccine. 2015;33:6164–72. doi:10.1016/j.vaccine.2015.09.081.
   PubMed Web of Science ®Google Scholar
• Li J, Li LK, Ma JF, Wei L-H, Niyazi M, Li C-Q, Xu A-D, Wang J-B, Liang H, Belinson J. Knowledge and attitudes about human papillomavirus (HPV) and HPV vaccines among women living in metropolitan and rural regions of China. Vaccine. 2009;27:1210–15. doi:10.1016/j.vaccine.2008.12.020.
   PubMed Web of Science ®Google Scholar
• Canfell K, Chesson H, Kulasingam SL, Berkhof J, Diaz M, Kim JJ. Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine. 2012;30(Suppl 5):F157–67. doi:10.1016/j.vaccine.2012.06.091.
   PubMedGoogle Scholar
• Liu YJ, Zhang Q, Hu SY, Zhao FH. Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China. BMC Cancer. 2016;16:164. doi:10.1186/s12885-016-2207-3.
   PubMed Web of Science ®Google Scholar
• Drolet M, Laprise JF, Boily MC, Franco EL, Brisson M. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. Int J Cancer. 2014;134:2264–68. doi:10.1002/ijc.28541.
   PubMed Web of Science ®Google Scholar
• Jit M, Chapman R, Hughes O, Choi YH. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ (Clinical Research Ed). 2011;343:d5775. doi:10.1136/bmj.d5775.
   PubMed Web of Science ®Google Scholar
• Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine. 2010;28:6858–67. doi:10.1016/j.vaccine.2010.08.030.
   PubMed Web of Science ®Google Scholar
• Choi YH, Jit M, Gay N, Cox A, Garnett GP, Edmunds WJ. Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine. 2010;28:4091–102. doi:10.1016/j.vaccine.2009.09.125.
   PubMed Web of Science ®Google Scholar